Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study

Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study

Objectives To compare a bDMARD mode of action cycle vs swap treatment strategy in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) after first tumour necrosis factor inhibitor (TNFi) discontinuation.Methods In December 2019, our local treatment protocol for PsA and axSpA ch...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nathan den Broeder, Noortje van Herwaarden, Alfons A den Broeder, Johanna E Vriezekolk, Emmerik F A Leijten, Elien Mahler, Ilse van Es, Lisan de Beijer
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-06-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/11/2/e005566.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
by: Philip J Mease, et al.
Published: (2019-06-01)

Self-disclosure and trust in the shared economy: a cross-cultural comparison
by: Peter Broeder
Published: (2023-07-01)

Cross-cultural impact of (in)genuine, smiling celebrities in online advertising
by: Peter Broeder, et al.
Published: (2019-10-01)

O impacto da marcação de produto na confiança e na intenção de compra: uma perspectiva intercultural no e-commerce visual
by: Peter Broeder, et al.
Published: (2022-01-01)

Comparative characteristics of axial spondyloarthritis and psoriatic arthritis with axial involvement
by: Е. Е. Gubar, et al.
Published: (2024-04-01)

Differential diagnosis of axial spondyloarthritis and psoriatic arthritis with axial involvement
by: E. E. Gubar, et al.
Published: (2025-06-01)

Enthesitis is a clue to the diagnosis of spondyloarthritis, focus on psoriatic arthritis
by: Ye. D. Yehudina, et al.
Published: (2021-02-01)

Tapering csDMARD or TNFi first: is the risk of flares different for ACPA-positive or ACPA-negative rheumatoid arthritis?
by: Annette H M van der Helm-van Mil, et al.
Published: (2024-09-01)

Zebrafish as a Model to Study the Role of Peroxisome Proliferating-Activated Receptors in Adipogenesis and Obesity
by: Marjo J. Den Broeder, et al.
Published: (2015-01-01)

Peripheral spondyloarthritis: a neglected entity—state of the art
by: Filip van den Bosch, et al.
Published: (2020-05-01)

Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2025-06-01)

Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis
by: Murat Torgutalp, et al.
Published: (2025-07-01)

Beyond inflammation: the molecular basis of bone remodeling in axial spondyloarthritis and psoriatic arthritis
by: Giuseppe Lopalco, et al.
Published: (2025-07-01)

Estimation of the sensitivity and specificity of ASAS criteria for peripheral spondyloarthritis in patients with early psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2015-09-01)

Case report of hypercalcemia-related kidney complications after discontinuation of denosumab
by: Gerrit van den Berg, et al.
Published: (2025-06-01)

Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance
by: Bogdan Batko, et al.
Published: (2024-07-01)

Specific features of axial spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, in persons of different genders
by: A. P. Rebrov, et al.
Published: (2015-03-01)

Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
by: Ellen-Margrethe Hauge, et al.
Published: (2019-07-01)

Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab
by: Ebru Atalar, et al.
Published: (2025-06-01)

Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
by: Emre Bilgin
Published: (2025-06-01)

Evaluation of the possibility of axial psoriatic arthritis patients meet classification criteria for axial spondyloarthritis and ankylosing spondylitis
by: E. E. Gubar, et al.
Published: (2023-08-01)

Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study
by: Bente Glintborg, et al.
Published: (2025-07-01)

Letter to the Editor Regarding “Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance”
by: Manjeet Kumar Goyal
Published: (2025-01-01)

Correction: Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study
Published: (2025-08-01)

Gender differences in psychological features and determinates of quality of life in axial spondyloarthritis and psoriatic arthritis: a cross-sectional study
by: Branko Ristic, et al.
Published: (2025-06-01)

Talking About Barriers to Disease-Modifying Anti-Rheumatic Drugs: Content Analysis of Audio-Recorded Routine Clinical Visits of Patients with Rheumatoid Arthritis
by: Voshaar MJH, et al.
Published: (2025-03-01)

Quantum SWAP gate realized with CZ and iSWAP gates in a superconducting architecture
by: Christian Križan, et al.
Published: (2025-01-01)

The duration of remission and minimal disease activity after initiation and discontinuation of biological agents in patients with early psoriatic arthritis (data from the all-russian psoriatic arthritis registry)
by: E. Yu. Loginova, et al.
Published: (2019-11-01)

Effectiveness and safety of secukinumab in axial spondyloarthritis and psoriatic arthritis: A retrospective analysis of its real-world usage from India
by: Sham Santhanam, et al.
Published: (2020-01-01)

Excited oscillons and charge-swapping
by: A. Alonso-Izquierdo, et al.
Published: (2025-07-01)

A Response to: Letter to the Editor Regarding “Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance”
by: Bogdan Batko, et al.
Published: (2025-01-01)

Effectiveness of Central Bank Swap Lines in Alleviating the Mispricing of FX Swaps at the Start of the COVID-19 Pandemic
by: Patty Duijm, et al.
Published: (2025-05-01)

Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease
by: Sofia Ramiro, et al.
Published: (2025-03-01)

Comparative analysis of the frequency of comorbid diseases in axial psoriatic arthritis and other variants of axial spondyloarthritis. Data from a hospital cohort
by: A. A. Yanushonite, et al.
Published: (2024-10-01)

Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab
by: Jan Brandt-Jürgens, et al.
Published: (2025-06-01)

Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?
by: Robert Landewé, et al.
Published: (2016-06-01)

Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial
by: Casper Webers, et al.
Published: (2025-07-01)

Tests of swap bodies monitoring system
by: A. A. Artyushin, et al.
Published: (2015-08-01)

Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
by: Marta Fabbroni, et al.
Published: (2014-01-01)

IS PSORIATIC ARTHRITIS REALLY PSORIATIC?
by: Sh. F. Erdes
Published: (2014-12-01)